Tokyo, Oct. 21 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000059474) titled 'Retrospective study of cisplatin plus etoposide therapy in patients with lung cancer undergoing hemodialysis: the largest single-regimen cohort' on Oct. 21.

Study Type: Observational

Primary Sponsor: Institute - Chiba University Hospital

Condition: Condition - Patients with Lung Cancer and end-stage renal failure undergoing HD Classification by malignancy - Malignancy Genomic information - NO

Objective: Narrative objectives1 - To explore the safety and efficacy of cisplatin and etoposide therapy in patients with end-stage renal disease undergoing maintenance hemodialysis Basic objectives2 - Safety

Eligibility: Age-lower limit - Not applicable Age-upper limit - Not applicable Gender - Male and Female Key inclusion criteria - The following cases meeting criteria 1) and 2) are eligible. 1) Cases treated with CDDP+ETP for advanced or recurrent lung cancer between January 2000 and December 2024. Cases previously treated with single-agent molecularly targeted therapy or single-agent immune checkpoint inhibitor therapy are eligible. 2) Cases undergoing maintenance hemodialysis prior to initiation of chemotherapy for end-stage renal failure. * Both small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are included. * Cases treated with chemoradiotherapy will be included for adverse event collection but excluded from overall survival data. Key exclusion criteria - Exclude cases meeting any of the following criteria: 1) Cases with cancer of unknown primary origin or cases receiving chemotherapy for malignant tumors other than lung cancer 2) Cases receiving chemotherapy for cancers other than lung cancer within six months prior to initiation of CDDP+ETP therapy 3) Cases requiring dialysis after starting chemotherapy for lung cancer 4) Cases receiving combination therapy with molecularly targeted drugs or immune checkpoint inhibitors alongside CDDP+ETP 5) Individuals who expressed refusal to participate in this study through the information disclosure document. Target Size - 15

Recruitment Status: Recruitment status - Preinitiation Date of protocol fixation - 2025 Year 05 Month 08 Day Anticipated trial start date - 2025 Year 05 Month 08 Day Last follow-up date - 2028 Year 05 Month 08 Day

To know more, visit https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068025

Disclaimer: Curated by HT Syndication.